Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis

Background: Peripheral T-cell lymphoma (PTCL) is an extensive class of biologically and clinically heterogeneous diseases with dismal outcomes. The histone deacetylase inhibitor (HDACi) romidepsin was approved for relapsed and refractory (R/R-PTCL) in 2011. This meta-analysis was performed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Jun, Han, Xinle, Lin, Suwen, Qiu, Chen, Zhu, Lijun, Huang, Zoufang, Hou, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602095/
https://www.ncbi.nlm.nih.gov/pubmed/34805202
http://dx.doi.org/10.3389/fmed.2021.732727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602095/
https://www.ncbi.nlm.nih.gov/pubmed/34805202
http://dx.doi.org/10.3389/fmed.2021.732727

Ejemplares similares